首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > 神經疾病 > 肌肉萎縮性側索硬化症(俗稱漸凍人)(ALS)治療藥物市場 ;開發平台分析及市場預測
產業/市場分類
製藥 (4816)
肥胖症治療 (44)
非專利藥 (129)
疫苗 (181)
神經疾病 (172)
骨頭疾病治療 (37)
動物用醫藥 (17)
處方藥 (156)
規章 (126)
感染疾病 (346)
精神病 (84)
製藥企業 (524)
糖尿病 (191)
癌症 (909)
藥物開發 (1449)
DDS (182)
OTC 非處方藥 (150)
市場調查報告書

肌肉萎縮性側索硬化症(俗稱漸凍人)(ALS)治療藥物市場 ;開發平台分析及市場預測

Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

出版商 GlobalData
出版日期 2011年09月 商品編碼 214925
內容資訊 英文 Pages: 80
價格
US $ 3500 PDF by E-mail (Single user license)
US $ 7000 PDF by E-mail (Site license)
US $ 10500 PDF by E-mail (Global license)


肌肉萎縮性側索硬化症(俗稱漸凍人)(ALS)治療藥物市場 ;開發平台分析及市場預測 是由出版商GlobalData在2011年09月所出版的。 這份英文市場調查報告書包含Pages: 80 價格從美金3500起跳。

簡介

本報告提供全球肌肉萎縮性側索硬化症(俗稱漸凍人)治療藥物市場相關的開發平台分析及市場預測，以市場特徵為首，評估分析競爭，開發平台等，再加入未來市場競爭、企業簡介等資料，為您概述為以下內容。

1 目錄

  • 1.1 表格一覽
  • 1.2 圖表一覽

2 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物: 簡介

  • 2.1 概要
  • 2.2 免疫學
  • 2.3 病因及病理學
  • 2.4 症狀
  • 2.5 診斷
  • 2.6 治療及管理模式
  • 2.7 詢問途徑
  • 2.8 GlobalData 開發平台報告指南

3 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物: 市場特性

  • 3.1 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場規模 - 全球
  • 3.2 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場預測 - 全球
  • 3.3 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場規模 - 美國
  • 3.4 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場預測 - 美國
  • 3.5 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場 - 法國
  • 3.6 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場預測 : 法國
  • 3.7 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場 - 德國
  • 3.8 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場預測 : 德國
  • 3.9 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場 - 義大利
  • 3.10 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場預測 : 義大利
  • 3.11 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場 - 西班牙
  • 3.12 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場預測 : 西班牙
  • 3.13 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場 - 英國
  • 3.14 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場預測 : 英國
  • 3.15 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場 - 日本
  • 3.16 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場預測 : 日本
  • 3.17 推動力與障礙; 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場
    • 3.17.1 推動力; 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場
    • 3.17.2 障礙; 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場
  • 3.18 機會及未飽合需求分析
  • 3.19 要點

4 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物: 競爭評估

  • 4.1 概要
  • 4.2 策略性競爭對手評估
  • 4.3 主要上市產品簡介 - 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場
    • 4.3.1 Rilutek (riluzole)

5 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物: 開發平台評估

  • 5.1 概要
  • 5.2 策略性開發平台評估
  • 5.3 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物 開發平台 - 各開發階段平台
    • 5.3.1 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物 - 第三階段平台
    • 5.3.2 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物 - 第二階段平台
    • 5.3.3 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物 - 第一階段平台
    • 5.3.4 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物 - 臨床實驗前平台
    • 5.3.5 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物 - 發現階段平台
    • 5.3.6 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物 - 未知階段
  • 5.4 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場 - 各作用機制平台
  • 5.5 技術趨勢的分析架構
  • 5.6 ALS 治療藥物 - 正在開發的最有潛力治療藥
  • 5.7 分子簡介;正在開發的潛力治療藥物
    • 5.7.1 Dexpramipexole (KNS-760704)
    • 5.7.2 Olesoxime (TRO 19622)
    • 5.7.3 Radicut
    • 5.7.4 ALS-02
  • 5.8 簡介; 其他臨床正在開發治療藥物
    • 5.8.1 E0302 (mecobalamin)

6 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物: 臨床實驗藍圖

  • 6.1 臨床實驗 各國 (US, EU5 & 日本)
  • 6.2 臨床實驗 各階段
  • 6.3 臨床實驗 各臨床實驗狀態
  • 6.4 有力的贊助商
  • 6.5 主要 參與治療藥物臨床實驗的企業

7 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物: 策略性評估

  • 7.1 影響未來市場的主要事件
  • 7.2 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物: 對於未來市場競爭的建議

8 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物: 有未來潛力的企業

  • 8.1 簡介
  • 8.2 企業簡介
    • 8.2.1 The Avicena Group Inc.
    • 8.2.2 Biogen Idec/Knopp Bioscience Inc.
    • 8.2.3 Actelion Pharmaceuticals Ltd.
    • 8.2.4 田邊三菱製藥
    • 8.2.5 Eisai Co. Ltd
    • 8.2.6 其他的企業 - 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場

9 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物: 授權合約及合作交易

10 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物: 附錄

  • 10.1 市場定義
  • 10.2 簡稱
  • 10.3 調查方法
    • 10.3.1 調查範圍
    • 10.3.2 二級研究
    • 10.3.3 預測
    • 10.3.4 主要研究
    • 10.3.5 專門委員會驗證
  • 10.4 諮詢方式
  • 10.5 免責聲明
  • 10.6 參考文獻

1.1 表格一覽

  • 表格 及1: 發生率;ALS - 前幾名7個國家全球
  • 表格 2: EI Escorial 為基礎 ALS 診斷標準
  • 表格 3: 對症治療藥物; ALS
  • 表格 4: 肌肉萎縮性側索硬化症(俗稱漸凍人) 全球治療藥物市場, 收益($m)
  • 表格 5: 肌肉萎縮性側索硬化症(俗稱漸凍人) 全球治療藥物市場，預測($m)
  • 表格 6: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 美國, 收益($m)
  • 表格 7: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 美國，預測($m)
  • 表格 8: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 法國, 收益($m)
  • 表格 9: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 法國，預測($m)
  • 表格 10: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 德國, 收益($m)
  • 表格 11: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 德國，預測 ($m)
  • 表格 12: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 義大利, 收益 ($m)
  • 表格 13: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 義大利，預測 ($m)
  • 表格 14: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 西班牙, 收益 ($m)
  • 表格 15: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 西班牙，預測 ($m)
  • 表格 16: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 英國, 收益 ($m)
  • 表格 17: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 英國，預測 ($m)
  • 表格 18: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 日本, 收益 ($m)
  • 表格 19: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 日本，預測 ($m)
  • 表格 20: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物 - 第三階段臨床實驗平台
  • 表格 21: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物 - 第二階段臨床實驗平台
  • 表格 22: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物 - 第一階段開發平台
  • 表格 23: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物 - 臨床實驗前平台
  • 表格 24: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物 - 發現階段平台
  • 表格 25: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物 - 未知階段
  • 表格 26:肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物 - 正在開發的最有潛力治療藥
  • 表格 27:開發的過程;dexpramipexole
  • 表格 28:開發的過程;olesoxime
  • 表格 29: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物, 臨床實驗 各國
  • 表格 30: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物, 全球, 臨床實驗, 各開發階段
  • 表格 31: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物, 全球, 臨床實驗 各臨床實驗狀態
  • 表格 32: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物, 全球, 臨床實驗 贊助商整體
  • 表格 33: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物, 全球, 臨床實驗 各有力贊助商
  • 表格 34: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物, 全球, 臨床實驗, 各前幾名企業
  • 表格 35: The Avicena Group Inc. - CNS 開發平台·投資組合
  • 表格 36: Biogen Idec. - CNS 開發平台·投資組合
  • 表格 37: Knopp Bioscience Inc. - CNS 開發平台·投資組合
  • 表格 38: Actelion Pharmaceuticals Ltd - CNS 開發平台·投資組合
  • 表格 39: 田邊三菱製藥 - CNS 開發平台·投資組合
  • 表格 40: Eisai公司 - CNS 開發平台·投資組合
  • 表格 41: 其他的企業 - 開發平台
  • 表格 42: 授權合約及合作交易

1.2 圖表一覽

  • 圖 1: 正常及ALS所侵害的神經細胞
  • 圖 2: 正常及ALS所侵害的運動神經原/肌肉
  • 圖 3: 管理研究;唾液分泌過多 - ALS患者
  • 圖 4: 管理研究;營養缺乏症 - ALS患者
  • 圖 5: 管理研究;呼吸困難 - ALS患者
  • 圖 6: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物, 詢問途徑
  • 圖 7: 肌肉萎縮性側索硬化症(俗稱漸凍人) 全球治療藥物市場, 收益($m)
  • 圖 8: 肌肉萎縮性側索硬化症(俗稱漸凍人) 全球治療藥物市場，預測 ($m)
  • 圖 9: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 美國, 收益($m)
  • 圖 10: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 美國，預測($m)
  • 圖 11: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 法國, 收益($m)
  • 圖 12: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 法國，預測($m)
  • 圖 13: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 德國, 收益($m)
  • 圖 14: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 德國，預測 ($m)
  • 圖 15: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 義大利, 收益 ($m)
  • 圖 16: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 義大利，預測 ($m)
  • 圖 17: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 西班牙, 收益 ($m)
  • 圖 18: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 西班牙，預測 ($m)
  • 圖 19: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 英國, 收益 ($m)
  • 圖 20: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 英國，預測 ($m)
  • 圖 21: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 日本, 收益 ($m)
  • 圖 22: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 日本，預測 ($m)
  • 圖 23: 機會及未飽和需求 - 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場
  • 圖 24: 主要上市產品的策略性競爭對手評估;肌肉萎縮性側索硬化症(俗稱漸凍人)
  • 圖 25: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物, 分子結構;Rilutek
  • 圖 26: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物, 各開發階段平台
  • 圖 27: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場 - 各作用機制平台
  • 圖 28: 技術趨勢的分析結構;肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物 開發平台
  • 圖 29: 技術趨勢的分析結構;肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物 開發平台 - 插圖說明
  • 圖 30: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物, 分子結構;dexpramipexole
  • 圖 31: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物, 分子結構;olesoxime
  • 圖 32: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物 - 臨床實驗 各國
  • 圖 33: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物, 全球, 臨床實驗, 各開發階段
  • 圖 34: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物, 全球, 臨床實驗 各臨床實驗狀態
  • 圖 35: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物, 全球, 臨床實驗 贊助商整體
  • 圖 36: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物, 全球, 臨床實驗 各有力贊助商
  • 圖 37: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物, 全球, 臨床實驗, 各前幾名企業
  • 圖 38: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場, 推動力與障礙
  • 圖 39: 對於未來市場競爭的建議 - 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物市場
  • 圖 40: 肌肉萎縮性側索硬化症(俗稱漸凍人) 治療藥物 - 不同企業臨床實驗平台

目錄

Abstract

Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Amyotrophic Lateral Sclerosis Therapeutics market. The report identifies the key trends shaping and driving the global Amyotrophic Lateral Sclerosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Amyotrophic Lateral Sclerosis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Amyotrophic Lateral Sclerosis Therapeutics market. Its scope includes -

  • Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Amyotrophic Lateral Sclerosis Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
  • Analysis of the current and future competition in the seven key countries Amyotrophic Lateral Sclerosis Therapeutics market.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Amyotrophic Lateral Sclerosis Therapeutics market.
  • Analysis of key recent licensing and partnership agreements in Amyotrophic Lateral Sclerosis Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Amyotrophic Lateral Sclerosis Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Amyotrophic Lateral Sclerosis Therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What's the next big thing in the global Amyotrophic Lateral Sclerosis Therapeutics market landscape? - Identify, understand and capitalize.

1 Table of Contents

1 Table of Contents 3

  • 1.1 List of Tables 5
  • 1.2 List of Figures 6

2 Amyotrophic Lateral Sclerosis Therapeutics: Introduction 7

  • 2.1 Overview 7
  • 2.2 Epidemiology 8
  • 2.3 Etiology and Pathophysiology 10
  • 2.4 Symptoms 10
  • 2.5 Diagnosis 11
  • 2.6 Treatment and Management Pattern 12
  • 2.7 Referral Pathway 16
  • 2.8 GlobalData Pipeline Report Guidance 17

3 Amyotrophic Lateral Sclerosis Therapeutics: Market Characterization 18

  • 3.1 Amyotrophic Lateral Sclerosis Therapeutics Market Size (2005 - 2010) - Global 18
  • 3.2 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018) - Global 19
  • 3.3 Amyotrophic Lateral Sclerosis Therapeutics Market Size (2005 - 2010): The US 20
  • 3.4 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010-2018): The US 21
  • 3.5 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): France 22
  • 3.6 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): France 23
  • 3.7 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): Germany 24
  • 3.8 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): Germany 25
  • 3.9 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): Italy 26
  • 3.10 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): Italy 27
  • 3.11 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): Spain 28
  • 3.12 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): Spain 29
  • 3.13 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): The UK 30
  • 3.14 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): The UK 31
  • 3.15 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): Japan 32
  • 3.16 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): Japan 33
  • 3.17 Drivers and Barriers for the Amyotrophic Lateral Sclerosis Therapeutics Market 34
    • 3.17.1 Drivers for the Amyotrophic Lateral Sclerosis Therapeutics Market 34
    • 3.17.2 Barriers for the Amyotrophic Lateral Sclerosis Therapeutics Market 34
  • 3.18 Opportunity and Unmet Need Analysis 35
  • 3.19 Key Takeaway 36

4 Amyotrophic Lateral Sclerosis Therapeutics: Competitive Assessment 37

  • 4.1 Overview 37
  • 4.2 Strategic Competitor Assessment 37
  • 4.3 Product Profile for the Major Marketed Products in the Amyotrophic Lateral Sclerosis Therapeutics Market 38
    • 4.3.1 Rilutek (riluzole) 38

5 Amyotrophic Lateral Sclerosis Therapeutics: Pipeline Assessment 40

  • 5.1 Overview 40
  • 5.2 Strategic Pipeline Assessment 40
  • 5.3 Amyotrophic Lateral Sclerosis Therapeutics Pipeline - Pipeline by Phases of Development 40
    • 5.3.1 Amyotrophic Lateral Sclerosis Therapeutics - Phase III Pipeline 41
    • 5.3.2 Amyotrophic Lateral Sclerosis Therapeutics - Phase II Pipeline 41
    • 5.3.3 Amyotrophic Lateral Sclerosis Therapeutics - Phase I Pipeline 42
    • 5.3.4 Amyotrophic Lateral Sclerosis Therapeutics - Preclinical Pipeline 42
    • 5.3.5 Amyotrophic Lateral Sclerosis Therapeutics - Discovery Pipeline 43
    • 5.3.6 Amyotrophic Lateral Sclerosis Therapeutics - Phase Unknown 43
  • 5.4 Amyotrophic Lateral Sclerosis Therapeutics Market - Pipeline by Mechanism of Action 44
  • 5.5 Technology Trends Analytical Framework 45
  • 5.6 ALS Therapeutics - Most Promising Drugs Under Development 46
  • 5.7 Molecule Profile for Promising Drugs under Development 47
    • 5.7.1 Dexpramipexole (KNS-760704) 47
    • 5.7.2 Olesoxime (TRO 19622) 49
    • 5.7.3 Radicut 50
    • 5.7.4 ALS-02 51
  • 5.8 Profile for Other Drugs under Clinical Development 52
    • 5.8.1 E0302 (mecobalamin) 52

6 Amyotrophic Lateral Sclerosis Therapeutics: Clinical Trials Mapping 53

  • 6.1 Clinical Trials by Country (US, EU5 & Japan) 53
  • 6.2 Clinical Trials by Phase 54
  • 6.3 Clinical Trials by Trial Status 55
  • 6.4 Prominent Sponsors 56
  • 6.5 Key Companies Participating in Therapeutics Clinical Trials 58

7 Amyotrophic Lateral Sclerosis Therapeutics: Stategic Assessment 59

  • 7.1 Key Events Impacting on the Future Market 59
  • 7.2 Amyotrophic Lateral Sclerosis Therapeutics: Implications for Future Market Competition 59

8 Amyotrophic Lateral Sclerosis Therapeutics: Future Players 61

  • 8.1 Introduction 61
  • 8.2 Company Profiles 62
    • 8.2.1 The Avicena Group Inc. 62
    • 8.2.2 Biogen Idec/Knopp Bioscience Inc. 62
    • 8.2.3 Actelion Pharmaceuticals Ltd. 64
    • 8.2.4 Mitsubishi Tanabe Pharma Corporation 64
    • 8.2.5 Eisai Co. Ltd 65
    • 8.2.6 Other Companies in the Amyotrophic Lateral Sclerosis Therapeutics Market 67

9 Amyotrophic Lateral Sclerosis Therapeutics: Licensing and Partnership Deals 72

10 Amyotrophic Lateral Sclerosis Therapeutics: Appendix 74

  • 10.1 Market Definitions 74
  • 10.2 Abbreviations 74
  • 10.3 Methodology 75
    • 10.3.1 Coverage 76
    • 10.3.2 Secondary Research 76
    • 10.3.3 Forecasting 76
    • 10.3.4 Primary Research 78
    • 10.3.5 Expert Panel Validation 78
  • 10.4 Contact Us 78
  • 10.5 Disclaimer 78
  • 10.6 Bibliography 79

1.1 List of Tables

  • Table 1: Incidence of ALS in Top Seven Countries and the World 9
  • Table 2: EI Escorial Criteria for Diagnosing ALS 11
  • Table 3: Drugs for the Symptomatic Treatment of ALS 12
  • Table 4: Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Revenue($m), 2005-2010 18
  • Table 5: Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Forecast($m), 2010-2018 20
  • Table 6: Amyotrophic Lateral Sclerosis Therapeutics Market, The US, Revenue($m), 2005-2010 20
  • Table 7: Amyotrophic Lateral Sclerosis Therapeutics Market, The US, Forecast($m), 2010-2018 21
  • Table 8: Amyotrophic Lateral Sclerosis Therapeutics Market, France, Revenue($m), 2005-2010 22
  • Table 9: Amyotrophic Lateral Sclerosis Therapeutics Market, France, Forecast($m), 2010-2018 23
  • Table 10: Amyotrophic Lateral Sclerosis Therapeutics Market, Germany, Revenue($m), 2005-2010 24
  • Table 11: Amyotrophic Lateral Sclerosis Therapeutics Market, Germany, Forecast ($m), 2010-2018 25
  • Table 12: Amyotrophic Lateral Sclerosis Therapeutics Market, Italy, Revenue ($m), 2005-2010 26
  • Table 13: Amyotrophic Lateral Sclerosis Therapeutics Market, Italy, Forecast ($m), 2010-2018 27
  • Table 14: Amyotrophic Lateral Sclerosis Therapeutics Market, Spain, Revenue ($m), 2005-2010 28
  • Table 15: Amyotrophic Lateral Sclerosis Therapeutics Market, Spain, Forecast ($m), 2010-2018 29
  • Table 16: Amyotrophic Lateral Sclerosis Therapeutics Market, UK, Revenue ($m), 2005-2010 30
  • Table 17: Amyotrophic Lateral Sclerosis Therapeutics Market, UK, Forecast ($m), 2010-2018 31
  • Table 18: Amyotrophic Lateral Sclerosis Therapeutics Market, Japan, Revenue ($m), 2005-2010 32
  • Table 19: Amyotrophic Lateral Sclerosis Therapeutics Market, Japan, Forecast ($m), 2010-2018 33
  • Table 20: Amyotrophic Lateral Sclerosis Therapeutics - Phase III Clinical Pipeline, 2011 41
  • Table 21: Amyotrophic Lateral Sclerosis Therapeutics - Phase II Clinical Pipeline, 2011 41
  • Table 22: Amyotrophic Lateral Sclerosis Therapeutics - Phase l Pipeline, 2011 42
  • Table 23: Amyotrophic Lateral Sclerosis Therapeutics - Preclinical Pipeline, 2011 42
  • Table 24: Amyotrophic Lateral Sclerosis Therapeutics - Discovery Pipeline, 2011 43
  • Table 25: Amyotrophic Lateral Sclerosis Therapeutics - Phase Unknown, 2011 43
  • Table 26:Amyotrophic Lateral Sclerosis Therapeutics - Most Promising Drugs Under Development, 2011 46
  • Table 27: A Brief History of dexpramipexole 47
  • Table 28: A Brief History of olesoxime 49
  • Table 29: Amyotrophic Lateral Sclerosis Therapeutics, Clinical Trials by Country,2011 53
  • Table 30: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Phase of Development, 2011 54
  • Table 31: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2011 55
  • Table 32: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Overall Sponsors, 2011 56
  • Table 33: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011 57
  • Table 34: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Top Companies, 2011 58
  • Table 35: The Avicena Group Inc. - CNS Pipeline Portfolio, 2011 62
  • Table 36: Biogen Idec. - CNS Pipeline Portfolio, 2011 63
  • Table 37: Knopp Bioscience Inc. - CNS Pipeline Portfolio, 2011 63
  • Table 38: Actelion Pharmaceuticals Ltd - CNS Pipeline Portfolio, 2011 64
  • Table 39: Mitsubishi Tanabe Pharma Corporation - CNS Pipeline Portfolio, 2011 65
  • Table 40: Eisai Co. Ltd. - CNS Pipeline Portfolio, 2011 66
  • Table 41: Other Companies in the Pipeline, 2011 67
  • Table 42: Licensing and Partnership Deals, 2010-2011 72

1.2 List of Figures

  • Figure 1: Normal and ALS-Affected Nerve Cells 7
  • Figure 2: Normal and ALS affected Motor Neurons/Muscles 8
  • Figure 3: Management Algorithm for Sialorrhea in Patients with ALS 13
  • Figure 4: Management Algorithm for Nutrition Deficiency in Patients with ALS 14
  • Figure 5: Management Algorithm for Respiratory Problems in Patients with ALS 15
  • Figure 6: Amyotrophic Lateral Sclerosis Therapeutics, Referral Pathway 16
  • Figure 7: Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Revenue($m), 2005-2010 18
  • Figure 8: Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Forecast ($m), 2010-2018 19
  • Figure 9: Amyotrophic Lateral Sclerosis Therapeutics Market, The US, Revenue($m), 2005-2010 20
  • Figure 10: Amyotrophic Lateral Sclerosis Therapeutics Market, The US, Forecast($m), 2010-2018 21
  • Figure 11: Amyotrophic Lateral Sclerosis Therapeutics Market, France, Revenue($m), 2005-2010 22
  • Figure 12: Amyotrophic Lateral Sclerosis Therapeutics Market, France, Forecast($m), 2010-2018 23
  • Figure 13: Amyotrophic Lateral Sclerosis Therapeutics Market, Germany, Revenue($m), 2005-2010 24
  • Figure 14: Amyotrophic Lateral Sclerosis Therapeutics Market, Germany, Forecast ($m), 2010-2018 25
  • Figure 15: Amyotrophic Lateral Sclerosis Therapeutics Market, Italy, Revenue ($m), 2005-2010 26
  • Figure 16: Amyotrophic Lateral Sclerosis Therapeutics Market, Italy, Forecast ($m), 2010-2018 27
  • Figure 17: Amyotrophic Lateral Sclerosis Therapeutics Market, Spain, Revenue ($m), 2005-2010 28
  • Figure 18: Amyotrophic Lateral Sclerosis Therapeutics Market, Spain, Forecast ($m), 2010-2018 29
  • Figure 19: Amyotrophic Lateral Sclerosis Therapeutics Market, UK, Revenue ($m), 2005-2010 30
  • Figure 20: Amyotrophic Lateral Sclerosis Therapeutics Market, UK, Forecast ($m), 2010-2018 31
  • Figure 21: Amyotrophic Lateral Sclerosis Therapeutics Market, Japan, Revenue ($m), 2005-2010 32
  • Figure 22: Amyotrophic Lateral Sclerosis Therapeutics Market, Japan, Forecast ($m), 2010-2018 33
  • Figure 23: Opportunity and Unmet Need in the Amyotrophic Lateral Sclerosis Therapeutics Market, 2010 35
  • Figure 24: Strategic Competitor Assessment of the Major Marketed Products for Amyotrophic Lateral Sclerosis, 2011 37
  • Figure 25: Amyotrophic Lateral Sclerosis Therapeutics, Molecular Structure of Rilutek 38
  • Figure 26: Amyotrophic Lateral Sclerosis Therapeutics, Pipeline by Phase of Development, 2011 40
  • Figure 27: Amyotrophic Lateral Sclerosis Therapeutics Market - Pipeline by Mechanism of Action, 2011 44
  • Figure 28: Technology Trends Analytic Framework of the Amyotrophic Lateral Sclerosis Therapeutics Pipeline, 2011 45
  • Figure 29: Technology Trends Analytic Framework of the Amyotrophic Lateral Sclerosis Therapeutics Pipeline - Description, 2011 46
  • Figure 30: Amyotrophic Lateral Sclerosis Therapeutics, Molecular Structure of dexpramipexole 47
  • Figure 31: Amyotrophic Lateral Sclerosis Therapeutics, Molecular Structure of olesoxime 49
  • Figure 32: Amyotrophic Lateral Sclerosis Therapeutics - Clinical Trials by Country, 2011 53
  • Figure 33: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Phase of Development, 2011 54
  • Figure 34: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2011 55
  • Figure 35: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Overall Sponsors, 2011 56
  • Figure 36: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011 57
  • Figure 37: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Top Companies, 2011 58
  • Figure 38: Amyotrophic Lateral Sclerosis Therapeutics Market, Drivers and Barriers, 2011 59
  • Figure 39: Implications for Future Market Competition in the Amyotrophic Lateral Sclerosis Therapeutics Market, 2011 59
  • Figure 40: Amyotrophic Lateral Sclerosis Therapeutics - Clinical Pipeline by Company, 2011 61
Back to Top